ImmunoGen, Inc. (NASDAQ:IMGN) Q2 2022 Results Conference Call July 29, 2022 8:00 AM ET

Company Participants

Anabel Chan - Head of Investor Relations

Mark Enyedy - President, CEO

Anna Berkenblit - CMO

Kristen Harrington-Smith - Chief Commercial Officer

Susan Altschuller - CFO

Conference Call Participants

John Newman - Canaccord Genuity

Michael Schmidt - Guggenheim Partners

Etzer Darout - BMO Capital Markets

Boris Peaker - Cowen

Andy Hsieh - William Blair

Kelly Shi - Jefferies

Swayampakula Ramakanth - H.C. Wainwright

Jonathan Chang - SVB Securities

Operator

Good morning and welcome to ImmunoGen's Second Quarter 2022 Financial and Operating Results Conference Call. Today's conference is being recorded.

At this time, I'd like to turn the call over to Anabel Chan, Head of Investor Relations. Please go ahead.

Anabel Chan

Good morning, and thank you for joining today's call. Earlier today, we issued a press release that includes a summary of our recent operating progress and second quarter 2022 financial results. This press release and a recording of this call can be found under the Investors & Media section of our website at immunogen.com.

With me today are Mark Enyedy, our President and CEO; Anna Berkenblit, our Chief Medical Officer; Kristen Harrington-Smith, our Chief Commercial Officer; and Susan Altschuller, our CFO. During today's call, we will review recent accomplishments for the business, our Q2 financial results, and highlight upcoming anticipated events.

We will be making forward-looking statements based on our current expectations and beliefs. These statements are subject to risks and uncertainties, and our actual results may differ materially, please consult the risks outlined in our press release issued this morning in the Risk Factors section of our most recent annual report on Form 10-K and quarterly report on Form 10-Q and in our other SEC filings, which are available at sec.gov and immunogen.com.

And with that, I'll turn the call over to Mark.

Mark Enyedy

Good morning, and thank you for joining us today. This past quarter, we made significant progress across the business, and importantly, FDA accepted the BLA for MIRV with a priority reviewed designation and set PDUFA date of November 28th. Our ongoing interactions with FDA have been productive and in conjunction with our mid cycle review, we were advised that the agency has no plans for an advisory committee at this time.

As we transition into a global fully integrated oncology company, we are actively preparing for the potential launch of MIRV monotherapy for patients with fully receptor alpha positive ovarian cancer.